Drug intelligence / Profile preview

GSK5251738

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules

Overview

GSK5251738 is an investigational small molecule agonist of Toll-like receptor 8 (TLR8) being developed by GSK for the treatment of chronic hepatitis B virus (HBV) infection. By targeting TLR8, which recognizes viral RNA, the drug triggers the innate immune system to produce antiviral cytokines and immunomodulatory factors. This approach is part of GSK's strategy to achieve a functional cure for HBV by enhancing the host's immune response against the virus. The asset, which was previously associated with the pipeline of GSK's former dermatology subsidiary Stiefel, is currently in Phase 1 clinical development.

Targets

TLR8 (Toll-like receptor 8)

Beyond the preview

Go deeper on GSK5251738.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK5251738.

Explore the full profile